Hims & Hers Health (HIMS) AI Stock Analysis

• Market Cap: $7.14B
• Dividend Yield: N/A
• Average Volume (3M): 12.91M
• Price to Earnings (P/E): 58.0
• Beta (1Y): 2.64
• Revenue Growth: 78.02%
• EPS Growth: 28.15%
• Country: US
• Employees: 1,637
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): 0.06
• Shares Outstanding: 219,270,890
• 10 Day Avg. Volume: 15,052,721
• 30 Day Avg. Volume: 12,909,598
• PEG Ratio: -0.07
• Price to Book (P/B): 10.95
• Price to Sales (P/S): 3.54
• P/FCF Ratio: 26.33
• Enterprise Value/Market Cap: 1.07
• Enterprise Value/Revenue: 3.46
• Enterprise Value/Gross Profit: 4.61
• Enterprise Value/Ebitda: 48.46
• 1Y Price Target: $42.88
• Price Target Upside: 36.63% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 11
• EPS Forecast (FY): 0.6
• Revenue Forecast (FY): $2.79B

• Rating: 68 Neutral
• Price Target: $34.00 ▲(8.35% Upside)

Hims & Hers Health's strong financial performance and positive earnings call guidance are offset by technical indicators suggesting bearish momentum and a high P/E ratio indicating overvaluation. The new share buyback program adds a positive strategic element, but high leverage remains a concern.

Positive Factors

Subscription-driven revenue growth

Sustained high revenue growth driven by subscriptions indicates durable demand and a scalable DTC telehealth model. Recurring plans improve predictability, enable efficient customer LTV payback, and support cross-selling of adjacent categories, underpinning multi-year expansion.

High gross and improving net margins

Very high gross margins reflect asset-light digital services and branded product economics, allowing material contribution to cover fixed costs. Improving net margins signal operating leverage as revenue scales, supporting sustainable profitability if margin pressures are managed.

Solid cash generation and conversion

Positive FCF growth and near-1.0 cash-to-income conversion show effective cash generation from core operations. Durable cash flow supports reinvestment, international expansion, buybacks and less reliance on external financing despite growth investments.

Negative Factors

High financial leverage

Elevated leverage increases interest and refinancing risk and limits financial flexibility for strategic initiatives. In a scaling business, high debt can constrain pace of international rollouts and category investments, elevating long-term execution and liquidity risk.

Gross margin pressure from product mix

Margin erosion tied to weight-loss fulfillment and revenue-per-shipment dynamics shows category unit-economics vulnerability. If durable, this mix shift can compress overall profitability and require pricing, fulfillment redesign, or higher volume to restore historical margins.

Rising G&A and integration costs

Incremental SG&A from acquisitions and expanded leadership increases fixed costs and delays operating leverage. Continued international integration (e.g., Zava) may require sustained investment, raising execution risk and pressuring near-to-medium-term margin expansion.

Hims & Hers Health Business Overview & Revenue Model

Company Description

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

How the Company Makes Money

Hims & Hers Health generates revenue through multiple streams, primarily by selling prescription medications and health-related products directly to consumers. The company operates on a subscription-based model for certain products, which provides recurring revenue. Additionally, HIMS earns income from telehealth consultations, where customers pay for access to healthcare providers. Strategic partnerships with pharmacies and healthcare networks also contribute to its revenue, enabling HIMS to efficiently distribute its products. The company's focus on branding and marketing enhances customer acquisition, further driving sales and profitability.

Hims & Hers Health Financial Statement Overview

Summary

Hims & Hers Health shows strong revenue growth and improved profitability, with a net profit margin of 9.62% and a positive cash flow growth rate. However, the high debt-to-equity ratio indicates significant leverage, posing a potential risk.

Income Statement

Hims & Hers Health has demonstrated strong revenue growth with a TTM revenue increase of 9.81%. The company has maintained a healthy gross profit margin of 76.20% and improved its net profit margin to 9.62% in the TTM period. EBIT and EBITDA margins have also shown positive trends, indicating improved operational efficiency. However, the gross profit margin has slightly decreased compared to the previous year.

Balance Sheet

The company has a high debt-to-equity ratio of 1.86 in the TTM period, indicating significant leverage. However, the return on equity has improved to 38.17%, showcasing effective use of equity to generate profits. The equity ratio stands at 26.00%, reflecting a moderate level of financial stability.

Cash Flow

Hims & Hers Health has shown a positive free cash flow growth rate of 10.07% in the TTM period, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.96, suggesting efficient conversion of income into cash. However, the free cash flow to net income ratio of 0.46 indicates room for improvement in cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.21B	1.48B	872.00M	526.92M	271.88M	148.76M
Gross Profit	1.66B	1.17B	714.95M	408.72M	204.49M	109.45M
EBITDA	157.91M	78.99M	-19.94M	-61.22M	-110.97M	-14.09M
Net Income	133.79M	126.04M	-23.55M	-65.68M	-107.66M	-18.11M
Balance Sheet
Total Assets	2.23B	707.54M	441.19M	366.34M	420.58M	118.70M
Cash, Cash Equivalents and Short-Term Investments	629.74M	300.25M	220.98M	179.63M	247.27M	100.21M
Total Debt	1.12B	11.35M	9.95M	5.31M	5.48M	0.00
Total Liabilities	1.65B	230.82M	97.16M	54.60M	85.97M	265.57M
Stockholders Equity	580.98M	476.72M	344.03M	311.74M	334.62M	-146.87M
Cash Flow
Free Cash Flow	131.54M	198.33M	46.99M	-33.78M	-39.42M	-6.71M
Operating Cash Flow	325.08M	251.08M	73.48M	-26.53M	-34.41M	-2.48M
Investing Cash Flow	-958.49M	-19.05M	-12.11M	34.70M	-156.27M	-39.70M
Financing Cash Flow	813.49M	-107.84M	-11.47M	-33.13M	235.04M	47.74M

Hims & Hers Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 31.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HIMS, the sentiment is Negative. The current price of 31.38 is below the 20-day moving average (MA) of 33.59, below the 50-day MA of 36.20, and below the 200-day MA of 45.77, indicating a bearish trend. The MACD of -1.58 indicates Positive momentum. The RSI at 35.17 is Neutral, neither overbought nor oversold. The STOCH value of 21.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HIMS.

Hims & Hers Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DOCS	73 Outperform	$7.77B	32.91	24.61%	―	20.21%	44.14%
HIMS	68 Neutral	$7.14B	58.01	26.21%	―	78.02%	28.15%
NUS	61 Neutral	$562.58M	5.30	14.55%	2.39%	-12.10%	―
GDRX	60 Neutral	$909.68M	31.20	4.90%	―	1.30%	―
EPC	58 Neutral	$872.17M	34.99	1.62%	3.51%	-1.34%	-73.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TDOC	47 Neutral	$1.11B	-4.91	-15.42%	―	-2.37%	77.85%

Hims & Hers Health Corporate Events

Hims & Hers Health Announces New Share Buyback Program

On November 13, 2025, Hims & Hers Health, Inc. announced a new share repurchase program allowing the company to buy back up to $250 million of its Class A common stock, set to expire in 2028. This initiative follows the completion of a prior repurchase program where the company bought back 1,334,572 shares for $55.5 million between October 1 and November 7, 2025, indicating a strategic move to manage its equity and potentially enhance shareholder value.

The most recent analyst rating on (HIMS) stock is a Hold with a $39.00 price target. To see the full list of analyst forecasts on Hims & Hers Health stock, see the HIMS Stock Forecast page.